NovaDel Pharma Announces Termination of License Agreements for Ondansetron Oral Spray Product

Published: Jan 23, 2012

BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Companies, Inc., relating to the development and commercialization of the Company’s ondansetron HCl oral spray product, effective as of January 16, 2012.

Back to news